Loading…
Loading…
DUL.DE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DUL.DE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DUL.DE and 80,000+ other tickers.
See exactly how DUL.DE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DUL.DE and 80,000+ other tickers.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies based on ribonucleic acid interference (RNAi) technology. The company's diverse pipeline of experimental RNAi therapeutics addresses a variety of serious conditions, including inherited genetic disorders, cardiometabolic ailments, hepatic infectious diseases, and diseases affecting the central nervous system (CNS) and eyes. Currently, Alnylam markets several key products: ONPATTRO (patisiran), an injection for adults suffering from polyneuropathy…
No recent news available.